Tag: Targeted Therapy

Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC

March 22, 2024 9:00 am

By Ryan Scott

Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more

Tumor Testing May Be Increasingly Useful in Ovarian Cancer

May 8, 2023 3:00 pm

Testing tumors with next-generation sequencing in patients with ovarian cancer can provide teams insight into targetable mutations that may affect treatment decisions, although this approach is not the current standard of care for all patients, an expert said.

Among 1,092 patients with ovarian cancer, 27.5% underwent next-generation sequencing; 96.1% had one or more genetic alteration; 25.9% had an alteration that aligned with targeted treatment

In an

… Read more